Quantcast

Latest Infliximab Stories

2011-05-25 07:30:00

LONDON, May 25, 2011 /PRNewswire/ -- Results from a Phase 2 multicenter, randomized, double-blind, proof-of-concept and dose-finding study showed that treatment with sirukumab (CNTO 136) improved signs and symptoms of rheumatoid arthritis (RA) in patients with active disease despite treatment with methotrexate (MTX). Findings from Part A of the two-part trial presented at the 2011 European League Against Rheumatism (EULAR) Congress showed that a greater proportion of patients receiving...

2011-05-25 07:00:00

SEOUL, Korea, May 25, 2011 /PRNewswire/ -- New findings presented from pooled analyses of the STELARA® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment. Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient...

2011-05-10 08:00:00

ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago. Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated...

2011-05-09 15:30:00

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population. The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in...

2011-05-09 07:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- New study findings showed that treatment with STELARA® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist. Investigators presented findings from a Phase 2b study at Digestive Disease Week, which showed nearly 40 percent of patients receiving STELARA 6 mg/kg achieved clinical...

2011-03-31 13:16:59

Speaking at the UK National Stem Cell Network annual science meeting later today (30 March), Professor Miguel Forte will describe research into a new cell therapy for chronic inflammatory conditions such as Crohn's disease. Patient's own blood cells are used to produce a type of cell "“ Type 1 T regulatory lymphocyte "“ that can reduce the extent of the disease. Professor Forte said "T regulatory lymphocytes are amazing cells "“ they secrete proteins "“ cytokines -...

2011-03-30 17:04:40

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community. Created as a guide for health care providers, the guidelines focus on the initiation and safety monitoring of multiple medications used in the treatment of JIA, including:     * Non-steroidal...

2296c9ac9c5a944551ae523e26ba9ce51
2011-03-04 18:55:00

Pfizer Inc. said on Friday that its rheumatoid arthritis drug met the main goals of a late-stage clinical trial. The drug is one of the most important in Pfizer's pipeline.  The company said the safety profile of the drug was consistent with that seen previously in the clinical program. The trial showed the drug reduced the signs and symptoms of rheumatoid arthritis by a statistically significant amount, compared with a placebo at six months. The trial tested the drug in patients with...

2011-03-02 07:00:00

ATLANTA and PORTLAND, Ore., March 2, 2011 /PRNewswire-USNewswire/ -- Two leading patient advocacy organizations have joined forces to educate people about psoriatic arthritis, an inflammatory disease that can lead to joint damage, especially if not diagnosed and treated early. The Joint Smart Coalition, launched today by the Arthritis Foundation and the National Psoriasis Foundation in collaboration with Amgen and Pfizer, aims to provide empowering and educational resources for people with...

2011-03-01 08:00:00

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "In addition, we made significant progress advancing a number of internal development programs,...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related